SCM
PALI icon

Squadron Capital Management’s Palisade Bio PALI Stock Holding History

Squadron Capital Management’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.27M Hold
3,000,000
– – 1.95% 13
2026
Q1 		$5.25M Sell
3,000,000
-1,500,000
-33% -$2.73M 1.92% 16
2025
Q4 		$10.6M Buy
+4,500,000
New +$8.65M 4.48% 6

Other funds holding PALI

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Squadron Capital Management's PALI Position: Q2 2026 in Review

Squadron Capital Management held its Palisade Bio (PALI) position steady in Q2 2026 at 3,000,000 shares worth $6.27M. The position accounts for 1.95% of the portfolio, ranked #13.

Squadron Capital Management first reported a position in PALI in Q4 2025 and has held it in 3 quarters since. The position peaked at $10.6M in Q4 2025. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

  • Squadron Capital Management held 3,000,000 shares of Palisade Bio worth $6.27M as of Q2 2026.
  • Squadron Capital Management left its Palisade Bio share count unchanged in Q2 2026.
  • Palisade Bio made up 1.95% of Squadron Capital Management's portfolio in Q2 2026, its #13 holding.
  • Squadron Capital Management first reported a position in Palisade Bio in Q4 2025 and has held it in 3 quarters since.
  • Squadron Capital Management's Palisade Bio position peaked at $10.6M in Q4 2025.
  • 124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on Squadron Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.